Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Advanced/Metastatic Breast Cancer, HER2-...
Phase PHASE2
Enrollment 57
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib — Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)
  • Drug: Trastuzumab (Herceptin) — Subcutaneous, 600mg Q3W; IV: 8mg/kg (loading) → 6mg/kg Q3W
  • Drug: Pertuzumab — IV: 840mg (loading) → 420mg Q3W
  • Drug: Pyrotinib — 240mg qd Week 1 → 320mg qd from Week 2 (max dose); loperamide prophylaxis for diarrhea
  • Drug: Endocrine Therapy 1 — Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)

Primary Outcomes

  • Progression-Free Survival (PFS) (From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-06-01
Completion: 2029-11-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Contact Information
Study Contact:
Chen Doctor Chen, PhD / Doctorate
02087341812
chenmt@sysucc.org.cn
Interventions
  • Drug: Dalpiciclib — Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)
  • Drug: Trastuzumab (Herceptin) — Subcutaneous, 600mg Q3W; IV: 8mg/kg (loading) → 6mg/kg Q3W
  • Drug: Pertuzumab — IV: 840mg (loading) → 420mg Q3W
  • Drug: Pyrotinib — 240mg qd Week 1 → 320mg qd from Week 2 (max dose); loperamide prophylaxis for diarrhea
  • Drug: Endocrine Therapy 1 — Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)
Study Locations (1 sites)
Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District, Guangdong, GUANGZHOU 510060 China
Eligibility Criteria
Inclusion Criteria: 1. Females aged 18 to 75 years with pathologically confirmed metastatic or locally advanced unresectable breast cancer. 2. Hormone receptor (HR)-positive and HER2-positive. 3. Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of first-line systemic anti-tumor therapy. 4. ECOG Performance Status: 0-1. Exclusion Criteria: 1. Symptomatic active brain metastases or extensive leptomeningeal metastases. 2. History of Grade 3 or 4 allergic reaction related to the study drugs. 3. Currently receiving other anti-tumor therapies.
Conditions Type 2 Diabetes Mellitus in Obese
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide. The main questions it aims to answer are: In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations: 1. Reduce the rate of decline in muscle mass? 2. Reduce the rate of decline in muscle strength? 3. Reduce the rate of decline in physical function? Participants will: Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Wegovy (2.4 Mg Dose) + exercise & nutrition — Participants will follow a 26-week, tri-weekly exercise program. One supervised 45-minute session will be conducted weekly via Zoom and recorded, with participants requested to repeat it twice independently on non-consecutive days. The program will include progressive resistance exercises alongside aerobic, balance, and flexibility training. Exercise intensity will be monitored using the Borg RPE scale, progressing gradually to a "somewhat hard" effort level (RPE 13-14). Weekly follow-up calls will track adherence and progress. The nutritional program will include individualized counseling, focusing on protein intake for sarcopenia prevention and personalized dietary adjustments based on health conditions and activity levels. Dietary intake will be monitored through food diaries and an adapted Food Frequency Questionnaire (FFQ). Weight will be tracked through self-reported measurements and on-site visits throughout the study.
  • Other: Wegovy (2.4 Mg Dose) + usual care — Participants allocated to the CG will receive general recommendations for PA according to the medical guidelines for PA for T2D. Guidelines recommend 150 minutes of moderate to vigorous-intensity aerobic activity per week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training. Incorporate 2-3 sessions/week of resistance exercise, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. PA habits will be collected through a questionnaire during the first and final visit. Nutritional guidance will focus on adequate protein intake and reduced carbohydrate consumption, emphasizing fiber-rich, minimally processed sources. Dietary intake will be evaluated through an FFQ and 3-day food diaries at baseline and study completion.

Primary Outcomes

  • Thigh muscle volume (TMV) (26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-11
Completion: 2027-11-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheba Medical Center
Collaborators: Hadassah Medical Organization
Principal Investigators:
  • Tali Cukierman - Yaffe, professor (PRINCIPAL_INVESTIGATOR) - Division of Endocrinology, Sheba Medical Center, Israel.
Contact Information
Study Contact:
Tali Cukierman - Yaffe, professor
0523824704
tcukierm@gmail.com
Tal Yahalom-Peri
0544647640
Tal.yahalom@gmail.com
Genya Aharon - Hananel, Dr.
+972 52-557-6455
Genyah@hadassah.org.il
Hadassah Medical Center
Interventions
  • Behavioral: Wegovy (2.4 Mg Dose) + exercise & nutrition — Participants will follow a 26-week, tri-weekly exercise program. One supervised 45-minute session will be conducted weekly via Zoom and recorded, with participants requested to repeat it twice independently on non-consecutive days. The program will include progressive resistance exercises alongside aerobic, balance, and flexibility training. Exercise intensity will be monitored using the Borg RPE scale, progressing gradually to a "somewhat hard" effort level (RPE 13-14). Weekly follow-up calls will track adherence and progress. The nutritional program will include individualized counseling, focusing on protein intake for sarcopenia prevention and personalized dietary adjustments based on health conditions and activity levels. Dietary intake will be monitored through food diaries and an adapted Food Frequency Questionnaire (FFQ). Weight will be tracked through self-reported measurements and on-site visits throughout the study.
  • Other: Wegovy (2.4 Mg Dose) + usual care — Participants allocated to the CG will receive general recommendations for PA according to the medical guidelines for PA for T2D. Guidelines recommend 150 minutes of moderate to vigorous-intensity aerobic activity per week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training. Incorporate 2-3 sessions/week of resistance exercise, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. PA habits will be collected through a questionnaire during the first and final visit. Nutritional guidance will focus on adequate protein intake and reduced carbohydrate consumption, emphasizing fiber-rich, minimally processed sources. Dietary intake will be evaluated through an FFQ and 3-day food diaries at baseline and study completion.
Study Locations (2 sites)
Hadassah Medical Center, Jerusalem, Israel 5251108 Israel
Sheba medical center, Ramat Gan, Israel 52621 Israel
Eligibility Criteria
Inclusion Criteria: 1. Patients 65 years and above. 2. Patients who were previously diagnosed with type 2 diabetes. 3. Overweight / obesity (body mass index, BMI ≥ 27 kg/m2). Exclusion Criteria: 1. Patients with significant hearing or visual disability. 2. Patients with Estimated Glomerular Filtration Rate (eGFR)\<30 ml/min/1.73 m2. 3. Patients who are in active nutritional therapy. 4. Patients who changed their diet recently (\< 1 month) and/or in a weight-loss program with \>5% weight loss or used anti-obesity drugs in the last 3 months. 5. Patients who reported a weight loss of \>5kg within 90 days of screening 6. Patients who were on Glucagon-like peptide-1 receptor agonists (GLP-1-RA) treatment during the last 3 months. 7. Patients with musculoskeletal disorders, which, by the judgment of the investigators, would limit their ability to perform the exercise training. 8. Patients with neurological diseases, which by the judgment of the investigators, would affect their ability to participate in the trial. 9. Patients with a history of amputation that impairs their ability to participate in the exercise program. 10. Patients with disabilities, which, by the judgment of the investigators, would affect their ability to participate in the trial. 11. Patients who use a walking aid. 12. Patients who are currently using systemic steroids. 13. Patients with active oncological diseases, excluding non-melanoma skin cancer. 14. Patients with diagnosed dementia or cognitive impairment that, in the view of the researchers, may impair their ability to sign a consent form or participate in the trial. 15. Patients who were hospitalized in the past month. 16. Patients who exercise regularly and in the eyes of the examiner will not benefit from the intervention program. 17. Anyone who is not suitable to participate in the study, according to the researcher's discretion. 18. Any contraindication to Magnetic resonance imaging (MRI) (e.g., MRI non-compatible cardiac implantable electronic device, metallic foreign bodies, implantable neurostimulation system, cochlear implants/ear implant, non-removable drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips which), or inability to perform an MRI scanner (e.g., claustrophobia). 19. Patients who do not fit within the measurement field of view of the Dual-energy X-ray absorptiometry (DXA) scanner in a supine position with the arms next to the body.
Conditions Diabetes Mellitus, Type I, Menstruation
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Continuous glucose monitors, as a technology that aims to improve glycaemic control in patients with type 1 diabetes, must always adjust to changes in blood glucose levels in these patients, e.g. during sporting activities. In women, in particular, menstruation and its different phases can affect blood glucose levels in different ways. Therefore, this study aims to determine whether there is a different behaviour of blood glucose levels during aerobic or high-intensity exercise in different phases of menstruation. If so, we will try to model this behaviour and create specific guidelines in this regard in terms of physical exercise programming in women. In addition, the information derived from this study will be used to design better artificial pancreas systems that take into account the effects of the menstrual cycle in women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Aerobic session — This session will consist of an aerobic training session performed on a cycle ergometer.
  • Other: HIIT session — The HIIT exercise will consist of strength exercises with elastic bands.

Primary Outcomes

  • Mean interstitial glucose (24 hours pre-intervention and 24 hours post-intervention)
  • Glycemic variability (24 hours pre-intervention and 24 hours post-intervention)
  • Time spent at each glucose range (24 hours pre-intervention and 24 hours post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-10
Completion: 2026-06
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Valencia
Collaborators: European Regional Development Fund
Contact Information
Study Contact:
Rodrigo Martín-San Agustín, Dr.
0034963983855
rodrigo.martin@uv.es
Rodrigo
963983855
rodrigo.martin@uv.es
University of Valencia
Interventions
  • Other: Aerobic session — This session will consist of an aerobic training session performed on a cycle ergometer.
  • Other: HIIT session — The HIIT exercise will consist of strength exercises with elastic bands.
Study Locations (1 sites)
University of Valencia, Valencia, Select One 46010 Spain
Eligibility Criteria
Inclusion Criteria: Age between 18-45 years T1D with a diabetes duration for more than 2 years Glycated hemoglobin (HbA1c) \< 8.5% (\<69 mmol mol-1) Stable insulin regimen in the past 6 months with less than 20% change in total insulin daily dose Multiple daily injections or insulin pump Weekly physical activity of 90 min or more, but no practicing any sport as amateur or professional. Exclusion Criteria: Clinical conditions or use of medications (other than insulin) known to affect glycemic control (e.g., oral/parenteral steroids or metformin, among others).
Conditions Obesity
Phase PHASE4
Enrollment 3000
Locations 30 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide — Administered SC
  • Other: Standard of Care — Standard of care

Primary Outcomes

  • Percent Change from Baseline in Body Weight (Baseline, 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-24
Completion: 2032-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Interventions
  • Drug: Tirzepatide — Administered SC
  • Other: Standard of Care — Standard of care
Study Locations (30 sites)
P91604 St John's Medical Centre, Altrincham, WA14 1PF United Kingdom
P89008 Ashton Medical Group, Ashton-under-Lyne, OL6 6EW United Kingdom
Y02319 SSP Bolton General Practice, Bolton, BL1 4TH United Kingdom
P83012 Tower Family Healthcare, Bury, BL9 0NJ United Kingdom
P91014 Washway Road Medical Centre, Cheshire, M33 7SS United Kingdom
P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House), Cheshire, SK8 5LL United Kingdom
Y02790 SSP Bolton Medical Centre, Great Lever, BL3 6PY United Kingdom
P89002 The Brooke Surgery, Hyde SK14, SK14 1AT United Kingdom
P84035 Bodey Medical Centre, Manchester, M14 6WP United Kingdom
P84630 The Arch Medical Practice, Manchester, M15 5TJ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Conditions Ketosis Prone Diabetes
Phase PHASE4
Enrollment 12
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitoring — After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
  • Drug: Insulin — Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.

Primary Outcomes

  • Quantify Changes in Blood Glucose (Up to 3 months)
  • Development of Mathematical Models (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-23
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Principal Investigators:
  • Priyathama Vellanki, MD, MS (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Priyathama Vellanki, MD, MS
(404) 778-1687
priyathama.vellanki@emory.edu
Interventions
  • Device: Continuous Glucose Monitoring — After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
  • Drug: Insulin — Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
Study Locations (2 sites)
Grady Health System, Atlanta, Georgia 30303 United States
Emory University Hospital Midtown, Atlanta, Georgia 30308 United States
Eligibility Criteria
Inclusion Criteria: * Provide informed consent * Have a BMI ≥ 28 kg/m2 * Be of African American ancestry * Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L. Exclusion Criteria: * Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes * Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism * Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies * Pregnant * Diagnosis of diabetes \> 90 days before the presentation of DKA * Unable to give consent
Conditions Proliferative Diabetic Retinopathy, Diab...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Single-session panretinal PRP (SS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
  • Procedure: Multiple-session panretinal PRP (MS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.

Primary Outcomes

  • Central subfield retinal thickness (CRT) (Baseline and 1, 3 and 6 months after treatment)
  • Vessel Perfusion Density (VPD) (Baseline and 1, 3 and 6 months after treatment)
  • Vessel Length Density (VLD) (Baseline and 1, 3 and 6 months after treatment)
  • Foveal Avascular Zone (FAZ) (Baseline and 1, 3 and 6 months after treatment)
  • Lesion size (Baseline and 1, 3 and 6 months after treatment)
  • Macular volume (Baseline and 1, 3 and 6 months after treatment)
  • Venular saturation (Baseline and 1, 3 and 6 months after treatment)
  • Arteriolar saturation (Baseline and 1, 3 and 6 months after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Principal Investigators:
  • Marita Andersson Grönlund, M.D. Prof (PRINCIPAL_INVESTIGATOR) - Göteborg University
Contact Information
Study Contact:
Imadeddin Abu Ishkheidem, M.D.
+46738744867
imadeddin.abu.ishkheidem@vgregion.se
Sofia Töyrä Silfverswärd, PhD
+46761283085
sofia.toyra.silfversward@vgregion.se
Imadeddin Abu Ishkheidem, M.D.
+46738744867
imadeddin.abu.ishkheidem@vgregion.se
Ögonmottagning Mölndal/SU
Interventions
  • Procedure: Single-session panretinal PRP (SS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
  • Procedure: Multiple-session panretinal PRP (MS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
Study Locations (1 sites)
Ögonmottagning Mölndal/SU, Mölndal, 43130 Sweden
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years. * Patients with type 1 or type 2 Diabetes Mellitus with newly diagnosed Proliferative Diabetic Retinopathy, PDR. * Visual acuity ≥ 0.1 Snellen. * CRT of less than 300 micrometer measured by OCT without cysts in the neuroretina. * Clear media and adequately dilated pupil for PRP. Exclusion Criteria: * Intraocular surgery within the last 4 months or planned within the next 3 months. * Previous or current center-involved diabetic macular edema (Ci-DME). * Previous PRP, intravitreal treatment (IVT), or macular laser treatment in study eye. * Treatment with medications known to risk macular edema. * Media opacity preventing adequate PRP. * General medical condition making office laser treatment very difficult or impossible.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences — This is a single group observational study with no interventions.

Primary Outcomes

  • The primary outcome is to collect and analyze continuous interstitial glucose measurements in 20 individuals with type 2 diabetes over a period of 20 days using a DEXCOM G7 continuous glucose monitor (CGM). (20 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-25
Completion: 2026-01-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Principal Investigators:
  • Andy Boyd, MD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
Laurie Quinn, PhD
312 771 6497
lquinn1@uic.edu
Sulaimon Balogun, PhD Student
773-971-0503
sbalog6@uic.edu
Laurie Quinn, PhD RN
312-996-7906
lquinn1@uic.edu
University of Illinois - Chicago
Interventions
  • Other: Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences — This is a single group observational study with no interventions.
Study Locations (2 sites)
University of Illinois - Chicago, Chicago, Illinois 60612 United States
University of Illinois College of Nursing, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria * People with diabetes in the 18-65 years of age range * Diagnosed with type 2 diabetes * Resides in the specified high social vulnerability zip codes - 60619, 60620, 60621, 60636, 60644, 60624, 60609, 60612, 60617, 60623, 60628, 60629, 60639, 60645, 60649, 60651, 60652, 60653 * Speak and understand the English language * Willing to wear various devices (CGM and sports wristband) * Own a smartphone Exclusion Criteria * Subjects will be excluded from the study for the following reasons: * Any concern of not understanding informed consent * Unable to understand or unwilling to follow research protocol
Conditions Insulin Resistance, Polycystic Ovary Syn...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ali Chappell
Principal Investigators:
  • Ali M Chappell (PRINCIPAL_INVESTIGATOR) - Insara
Contact Information
Study Contact:
Ali M Chappell, PhD, MS, RD
4092070443
research@insara.com
Ali M Chappell, PhD, MS, RD
8064417275
achappell@lillihealth.com
Lilli Health
Interventions
N/A
Study Locations (1 sites)
Lilli Health, Houston, Texas 77554 United States
Eligibility Criteria
Inclusion Criteria Age: Participants aged 18+ years Sex: Both males and females Race/Ethnicity: Participants from diverse racial and ethnic backgrounds BMI: Participants across a range of body mass index (BMI) values PCOS Diagnosis: Participants with and without a confirmed diagnosis of PCOS based on established diagnostic criteria Participants must have completed metabolic testing within one month prior to enrollment, including: * Fasting insulin * Hemoglobin A1c (A1c) * Complete lipid panel * Triglycerides Laboratory testing must be completed through a healthcare provider, an independent laboratory, or by using an Insara Insulin Testing Kit Laboratory values must be obtained following a minimum 8-hour fast Participants must have complete laboratory data for all required measures Exclusion Criteria Age: Participants below 18 years Sex: None. Both males and females are included Race/Ethnicity: None. Participants from all racial and ethnic backgrounds are included Endocrine Disorders: Participants with other endocrine disorders affecting insulin levels (e.g., insulin-secreting tumors) Significant recent weight change: Loss of more than 5% of body weight within the previous month Pregnancy or breastfeeding Acute illness or infection within the past 2 weeks Use of medications known to significantly affect insulin or glucose metabolism will be recorded and accounted for in analysis
Conditions Chronic Kidney Disease
Phase PHASE1
Enrollment 124
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: AZD4248 — AZD4248 will be administered orally.
  • Drug: Placebo — Placebo will be administered orally.
  • Drug: AZD4248 — AZD4248 will be administered via IV infusion.
  • Drug: Placebo — Placebo will be administered via IV infusion.

Primary Outcomes

  • Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days))
  • Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements (Day 1 to Day 169)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-06-09
Completion: 2026-12-25
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Collaborators: Parexel
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: AZD4248 — AZD4248 will be administered orally.
  • Drug: Placebo — Placebo will be administered orally.
  • Drug: AZD4248 — AZD4248 will be administered via IV infusion.
  • Drug: Placebo — Placebo will be administered via IV infusion.
Study Locations (5 sites)
Research Site, Glendale, California 91206 United States
Research Site, Chicago, Illinois 60643 United States
Research Site, Ann Arbor, Michigan 48109 United States
Research Site, Saint Paul, Minnesota 55114 United States
Research Site, San Antonio, Texas 78215 United States
Eligibility Criteria
Key Inclusion Criteria: \- Healthy participants with suitable veins for cannulation or repeated venipuncture. Parts A and B: * Have a body mass index (BMI) between 18 and 30 kilograms per millimeter (kg/m2), inclusive. * For Chinese participants (Part A2): participants are to be Chinese, defined as having both parents and 4 grandparents who are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China. * For Japanese participants (Part B2): participants are to be Japanese, defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan. Part C: * Have a BMI between 20 and 40 kg/m2, inclusive. * Have a diagnosis of diabetic kidney disease (DKD). * Hemoglobin A1C (HbA1c) of ≤ 10.5%. * Participants are required to be on a stable dose of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening. Part D: * Have a BMI between 20 and 35 kg/m2, inclusive. * Have a diagnosis of DKD as defined by a) diagnosis of type 2 diabetes (T2D) b) eGFR values and c) urine albumin to creatinine ratio (UACR) values. * HbA1c of ≤ 10.5%. * Participants are required to be on a stable dose of ACEi or ARB for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening. * Participants must be able and motivated to use the home creatinine device and smartphone independently by successfully performing the test without assistance from site staff. * Participants must be able to read and understand English sufficient to participate in site visits and home testing. Key Exclusion Criteria: * History of any clinically important disease or disorder which may put the participant at risk because of participation in the study or influence the results. * Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or human immunodeficiency virus (HIV). Parts A and B: * History or presence of gastrointestinal, hepatic, or renal disease. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248. * Participants who have previously received AZD4248. Part C: * History or presence of gastrointestinal, hepatic, or renal disease. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248. * Use of drugs that are strong or moderate CYP3A4 inhibitors/inducers or P-gp inhibitors from within 3 weeks before Screening until the end of the last sample collection. * Participants who have previously received AZD4248. * Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry. * Expected change of dosing regimen during the study. * History of clinically significant heart or vascular disease. * New York Heart Association Class 2, 3, or 4 or history of hospitalization for heart failure within 6 months of screening. * Ventricular arrhythmias requiring treatment. * Amputation due to peripheral artery disease. * Severe chronic obstructive pulmonary disease as judged by the Investigator or hospitalization for exacerbation in the last 6 months. Part D: * Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry. * Expected change of dosing regimen during the study.

Microbiome and Atopy in Mali

NCT07051902
Recruiting
Conditions Atopic Disease
Phase Not Applicable
Enrollment 288
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes. In this study, the investigators will look for clues about things that may affect whether people get allergic diseases. The investigators will look at things on or in the body, like germs, and things in the environment, like pollution. To do this, the investigators will collect different types of biological samples, health information, and environmental information from people with allergic diseases and people without allergic diseases. The investigators will compare what is found in each group to look for differences that might be related to allergic disease.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Differences in gut microbiome between atopic patients and healthy controls in children and adults. (Within 28 days after the screening visit.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-30
Completion: 2026-12
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: true
Enrollment: 288 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • Ian Myles, MD (PRINCIPAL_INVESTIGATOR) - NIAID, National Institutes of Health (NIH)
  • Kingsley Osei-Karikari (STUDY_CHAIR) - National Institutes of Health (NIH)
Contact Information
Study Contact:
Cisse Lamissa, MD
+223 66956944
lamissa05@gmail.com
Khadida Ouattara, MD, MSc
+223 66780357
zankhadi@gmail.com
Cisse Lamissa, MD
+223 66956944
lamissa05@gmail.com
Dermatology Hospital of Bamako
Interventions
N/A
Study Locations (2 sites)
Dermatology Hospital of Bamako, Bamako, Mali
Pneumology Ward, Point G University Hospital, Bamako, Mali
Eligibility Criteria
Inclusion Criteria (Study Group): * Aged ≥3 years. * Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \<18 years). * Positive Screening questionnaire for asthma or eczema. * Diagnosed with atopic dermatitis or asthma via physician diagnosis and criteria as follows: * Clinical diagnosis of atopic disease, as defined by Hanifin and Rajka criteria, that has been present for ≥3 months before the screening visit. Inclusion Criteria (Healthy Volunteers): * Aged ≥3 years. * Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \<18 years). * Negative Screening questionnaire for asthma and eczema. * In good general health as evidenced by medical history and not diagnosed with atopic dermatitis or asthma via physician diagnosis. * Failure to meet Hanifin and Rajka criteria and \<3 on GINA guidelines for asthma diagnosis. * No self-reported history of food allergy. Exclusion Criteria: * Use of antibiotics in the 3 months prior to screening. * Current pregnancy or lactation (determined by self-report). * Treatment with an investigational drug within 12 months prior to screening. * Current smoker or tobacco use within 4 months prior to screening. * Current skin infections other than atopic dermatitis (e.g., scabies). * Active diarrhea as defined by three or more loose stools per day (Bristol stool scale score of 6 or 7). * Presence of current bacterial, viral, or fungal infection, with the exception of isolated onchomycosis, which is not exclusionary. * Any other condition or factor that the investigator determines may significantly influence the results of testing.
Conditions Chronic Cough (CC), Asthma
Phase PHASE1
Enrollment 33
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.

Primary Outcomes

  • The mean %FEV1 change from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of wheeze measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of chest tightness measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of shortness of breath measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The mean change in oxygen saturations (SpO2) from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The intra-class correlation of measures obtained from repeat ATP cough challenges (Baseline to 1 week)
  • The frequency of adverse events (Baseline to 1 week)
  • Total maximum number of evoked coughs (Emax) by any dose of ATP (Until the end of the ATP cough challenge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-05
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McMaster University
Contact Information
Study Contact:
Imran Satia, MD PhD
905-525-2100
satiai@mcmaster.ca
Imran Satia, MD PhD
905-521-2100
satiai@mcmaster.ca
Respiratory Research Lab
Interventions
  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
Study Locations (1 sites)
Respiratory Research Lab, Hamilton, Ontario L8N 3Z5 Canada
Eligibility Criteria
Phase 1: Healthy individuals Inclusion Criteria: Eligible participants in Phase 1 will include healthy adults (≥18 years old) with: 1. Normal spirometry; and 2. No current or past medical history of chronic cough or other respiratory diseases. Exclusion Criteria: We will exclude healthy individuals meeting the following: (1) Are a current or former smoker with a \>5 pack-year history and abstinence ≤6 months; 1. Unable to perform acceptable and reproducible spirometry; 2. Have unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Have had a lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; or 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study. 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Women of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening. Phase 2: Patients with RCC/UCC and mild-steroid naïve asthma Inclusion Criteria: Eligible participants will include adults (≥18 years old) with: 1. RCC/UCC for \>1 year, demonstrated by a normal chest radiograph and no airflow obstruction (FEV1/FVC\>0.7/LLN) with either: 1. Insufficient improvement in cough despite treatment targeting any underlying condition(s) contributing to the cough (RCC); or 2. Cough for which an underlying cause has not been determined despite thorough investigation (UCC). 2. Mild steroid-naïve asthma who demonstrate evidence of a positive screening methacholine (PC20\<16 mg/mL); symptoms of cough, shortness of breath, chest tightness, and wheeze, that, in the opinion of the qualified investigator, are well-controlled; and those have not used inhaled or oral corticosteroids for the past month. Exclusion Criteria: Cohort-specific exclusion criteria include the following: For the RCC/UCC cohort: (1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; For the mild steroid-naïve asthma cohort: 1. Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; 2. History or exacerbation or uncontrolled symptoms within the last month prior to the first study visit; and 3. Use of inhaled or oral corticosteroids within the last month prior to the first study visit. We will exclude participants meeting any of the following criteria from the study: 1. Unable to perform acceptable and reproducible spirometry; 2. Unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study; 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Female participants of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study; 2. Have not been using hormonal birth control for a minimum of 3 months prior to screening.
Conditions Obstructive Pulmonary Disease, Mechanica...
Phase NA
Enrollment 10
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this physiological pilot study with a randomized crossover design is to study the effect of Flow-controlled ventilation (FCV) on the minute volume compared to Volume-controlled ventilation (VCV) in intubated patients with an exacerbation of their asthma or COPD. Our hypothesis is that FCV will results in a lower minute volume compared to VCV in this patient category. Patients will be randomized between two ventilation sequences, namely 90 minutes of FCV followed by 90 minutes of VCV or vice versa.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: FCV — 90 minutes of FCV

Primary Outcomes

  • MV (90 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-17
Completion: 2027-10
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Erasmus Medical Center
Collaborators: Maasstad Hospital
Principal Investigators:
  • Diederik P Gommers, Prof. Dr. (STUDY_DIRECTOR) - Erasmus Medical Center
Contact Information
Study Contact:
Julien P Van Oosten, MD
+31630600232
j.vanoosten@erasmusmc.nl
Annemijn H Jonkman, Dr.
+31627858466
a.jonkman@erasmusmc.nl
Gommers, Professor
0031107035142
d.gommers@erasmusmc.nl
Erasmus Medical Center
Interventions
  • Device: FCV — 90 minutes of FCV
Study Locations (2 sites)
Erasmus Medical Center, Rotterdam, South Holland 3015 GD Netherlands
Maasstad Hospital, Rotterdam, South Holland 3079DZ Netherlands
Eligibility Criteria
Inclusion Criteria: * 18 years or older; * Provided written informed consent; * Undergoing controlled mechanical ventilation via an endotracheal tube; * Reason for intubation being exacerbation of asthma or COPD; * Intubated ≤72 hours Exclusion Criteria: * Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift) * Untreated pneumothorax (i.e. no pleural drainage) * Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and/or vasopressors or a noradrenalin dose \>0.5mcrg/kg/min * High (\>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure * An inner tube diameter of 6mm or less * Anticipating withdrawal of life support and/or shift to palliation as the goal of care * Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.: * Have a thorax circumference inappropriate for EIT-belt * Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt * Recent (\<7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation * ICD device present (potential interference with proper functioning of the EIT device and ICD device) * Excessive subcutaneous emphysema * Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.: * Recent esophageal surgery * Prior esophagectomy * Known presence of esophageal varices * Severe bleeding disorders